Bolt Biotherapeutics’ (BOLT) Buy Rating Reaffirmed at HC Wainwright

Bolt Biotherapeutics (NASDAQ:BOLT)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a report released on Thursday,Benzinga reports. They currently have a $7.00 target price on the stock. HC Wainwright’s price target would indicate a potential upside of 32.58% from the company’s current price.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Bolt Biotherapeutics in a report on Monday, April 20th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Bolt Biotherapeutics currently has a consensus rating of “Hold” and a consensus target price of $41.00.

Bolt Biotherapeutics Price Performance

Bolt Biotherapeutics stock opened at $5.28 on Thursday. The company has a debt-to-equity ratio of 0.98, a quick ratio of 3.51 and a current ratio of 3.51. Bolt Biotherapeutics has a 52 week low of $3.91 and a 52 week high of $7.35. The stock has a market capitalization of $10.14 million, a P/E ratio of -0.32 and a beta of 1.10. The stock has a fifty day moving average of $4.71 and a 200-day moving average of $5.08.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($4.31) EPS for the quarter, missing analysts’ consensus estimates of ($2.85) by ($1.46). Bolt Biotherapeutics had a negative return on equity of 100.89% and a negative net margin of 455.15%.The business had revenue of $0.03 million for the quarter, compared to analyst estimates of $1.50 million. On average, sell-side analysts expect that Bolt Biotherapeutics will post -9.54 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Bolt Biotherapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC grew its position in Bolt Biotherapeutics by 40.3% during the 1st quarter. Renaissance Technologies LLC now owns 77,225 shares of the company’s stock worth $312,000 after acquiring an additional 22,200 shares during the last quarter. T3 Companies LLC bought a new stake in Bolt Biotherapeutics during the 4th quarter worth $208,000. Nano Cap New Millennium Growth Fund L P bought a new stake in Bolt Biotherapeutics during the 4th quarter worth $112,000. Susquehanna International Group LLP bought a new stake in shares of Bolt Biotherapeutics in the 3rd quarter valued at about $89,000. Finally, Shay Capital LLC bought a new stake in shares of Bolt Biotherapeutics in the 3rd quarter valued at about $85,000. Institutional investors own 86.70% of the company’s stock.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.